DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Zanubrutinib Combined With G-CVP in Previously Untreated FL

Phase 2

Recruiting

Conditions: Follicular Lymphoma ( FL)

Interventions: Drug: zanubrutinib, obinutuzumab,combined with CVP

First Posted Date: 2025-05-07

Last Posted Date: 2025-05-07

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT06959732

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

Phase 2

Recruiting

Conditions: HER2 Positive Breast Cancer
Pyrotinib Treatment

Interventions: Drug: pyrotinib

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 964

Registration Number: NCT06958627

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC

Completed

Conditions: Stage II-III Non-small Cell Lung Cancer
Concurrent Chemotherapy
Conditions Influencing Health Status

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 213

Registration Number: NCT06958614

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.

Early Phase 1

Recruiting

Conditions: Advanced Lung Cancer
Lung Metastasis

Interventions: Biological: BMD006 monotreatment
Biological: BMD006 in combination with PD-1 antibody

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 22

Registration Number: NCT06928922

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

Phase 2

Not yet recruiting

Conditions: Solid Tumors
Children
Adolescent
Chemotherapy Induced Neutropenia

Interventions: Drug: Telpegfilgrastim Injection
Drug: filgrastim

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 132

Registration Number: NCT06926751

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Triple-Negative Breast Cancer (TNBC)
Neoadjuvant Therapy

Interventions: Drug: paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab

First Posted Date: 2025-04-04

Last Posted Date: 2025-04-04

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 32

Registration Number: NCT06910072

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: HER2-Negative Locally Advanced Breast Cancer

Interventions: Drug: Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy
Drug: Neoadjuvant Chemotherapy Combined with Immunotherapy

First Posted Date: 2025-04-03

Last Posted Date: 2025-04-03

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 170

Registration Number: NCT06908668

Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer

Not yet recruiting

Conditions: Colorectal Cancer (CRC)
Neoadjuvant Therapy
Proteomics

First Posted Date: 2025-04-01

Last Posted Date: 2025-04-01

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 400

Registration Number: NCT06904677

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Chaoyang district, China

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)
II-IIIB

Interventions: Drug: QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed
Drug: QL1706

First Posted Date: 2025-03-26

Last Posted Date: 2025-03-26

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT06897046

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Not yet recruiting

Conditions: Esophageal Cancer

First Posted Date: 2025-03-21

Last Posted Date: 2025-03-21

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 600

Registration Number: NCT06889402

Locations: 🇨🇳
Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy